Recent Finacing
Recent Raise
Clinical-stage biopharmaceutical company based in Rehovot and Wilmington developing pan‑Notch gamma‑secretase inhibitors AL101 (P2 ACC; planned P2 in Notch‑mutant TNBC) and AL102 (hematologic malignancies; Novartis collaboration in multiple myeloma).
